PLOS Medicine 'Under Review': What Each Status Means and When to Expect a Decision

A PLOS Medicine staff editor assesses scope and quality, and the professional editor and Academic Editor decide whether the work warrants peer review: whether it is likely to provide a major advance in a particular field and describe a sufficient body of work to support that claim. As of early 2017, about 20% of initial submissions were invited to a full submission, and PLOS says 91% of research submissions receive an initial decision within 5 days.

PLOS Medicine says rejected manuscripts generally do not fit its criteria in terms of originality, importance to the field, cross-disciplinary interest, or sound methodology.

The PLOS Medicine journal office receives the initial submission: a manuscript with a title page, a cover letter, figures, and supporting information if relevant. Trial registration, ethics approvals, competing-interest and funding statements, data-availability details, and reporting checklists are requested at full submission. The practical risk is not only missing files; it is a methods section or data statement that cannot support the clinical or policy claim in the abstract.

The PLOS Medicine staff editor reads the paper and assesses scope and quality, working with an Academic Editor. The initial submission process allows authors to quickly submit and obtain rapid feedback from the editors.

Research articles receive oversight from an independent Academic Editor expert in the field, alongside the professional staff editors. PLOS Medicine editors select potential reviewers based on their expertise in research areas relevant to the manuscript.

Reviewer invitations are sent by email from the journal's Editorial Manager submission system. PLOS Medicine does not publish a reviewer count or a recruitment window.

Once reviewers agree to review, PLOS Medicine asks them to aim to complete the review within 8 days. Reviewers are asked whether the claims are significant and supported by the data and analyses, whether the methodology is detailed enough for the work to be reproduced, whether the study conforms to relevant reporting guidelines, and whether the article is accessible to non-specialists. PLOS Medicine uses single-anonymized peer review by default; authors can opt in to publish the peer review history alongside accepted papers.

After reports return, the professional editor and Academic Editor consider the reviewer feedback together with their own evaluations. The editors make the final decision on whether to publish each submission based on the reviewers' comments, the PLOS Medicine criteria for publication, and their own assessment of the manuscript.

• Decline within 1 to 5 days: Administrative issue or immediate scope mismatch.

• Decline within about a week: In-house editor initial screening decline (PLOS says 91% of research submissions receive an initial decision within 5 days).

• Still Under Review after 3 weeks: Strong signal. Paper passed the in-house editor screening.

• Still Under Review after 14 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the Editorial Manager portal is appropriate.

• Status changes to "Decision Pending": Reports are in; the editors are working toward a decision.

This is the most common anxiety we hear from PLOS Medicine authors during the active editorial window. The honest answer: no, 8 weeks at Under Review is within the usual range, since PLOS's metrics page lists a median of 67 days (about 9.5 weeks) to first decision for 2025. Reports may already be in editorial synthesis with the Academic Editor preparing the recommendation for the in-house handling editor's final decision.

Most reviewer-driven delays come from reviewer-recruitment timing rather than slow reviews because PLOS Medicine recruits topic-matched general-medicine clinical-research reviewers. If the portal still says Under Review at the 12-week mark, one possible explanation is that one of the assigned reviewers asked for an extension.

The better use of the 8-to-12-week window is to audit the revision package reviewers are likely to request: abstract clinical or policy claim, first table and figure logic, statistical-methods detail, data availability, ethics documentation, and the response-letter skeleton. A status note at 8 weeks rarely changes reviewer behavior, but a prepared response file can shorten a later revision by several days.

If your PLOS Medicine paper is rejected after review, the natural cascade depends on what the reviewers and editor cited:

PLOS ONE is the natural PLOS cascade for clinical-research papers where the general-medicine relevance bar of PLOS Medicine is not met but the rigor is high. PLOS supports manuscript-transfer with reviewer reports preserved.

PLOS Global Public Health is the PLOS cascade for global-health-focused clinical-research papers.

PLOS Digital Health is the PLOS cascade for digital-health and AI-clinical-research papers.

BMJ Open is the BMJ open-access general-medicine cascade. BMJ Open uses ScholarOne at ScholarOne submission portal; editorial contact editorial.bmjopen@bmj.com.

The Lancet Public Health is the Lancet specialty open-access cascade for public-health clinical-research. The Lancet uses Editorial Manager at Editorial Manager submission portal; editorial contact editorial@lancet.com.

NEJM Evidence is the NEJM open-access cascade for clinical-research papers. NEJM uses ScholarOne at ScholarOne submission portal; editorial contact nejm@nejm.org.

PLOS Medicine's reviewer guidelines ask reviewers a set of questions, and four of them drive most manuscript preparation. The table below maps each to actionable preparation.

In our pre-submission work with PLOS Medicine-targeted manuscripts, three named patterns generate the most consistent reviewer concerns and the most common reasons papers miss the editorial bar or fail the initial screening.

Specialty-only framing flagged at in-house editor initial screening. When the introduction frames the work too narrowly without general-medicine readership relevance, in-house handling editor initial screening decline within about a week is common. The strongest manuscripts frame the introduction around an implication for general-medicine practice that would matter to the broad PLOS Medicine readership.

Check whether your PLOS Medicine framing reaches a general-medicine audience →

Methods documentation gaps surface at initial screening. When methods documentation is thin (especially for specialized techniques, custom analysis pipelines, or complex statistical models), the in-house handling editor can flag concerns at the initial assessment. The strongest manuscripts include methods sufficient for replication before submission.

Check whether your methods section is reviewable →

Data-conclusion alignment flagged by Academic Editor. When conclusions exceed what the data clearly support (especially causal claims from observational data or generalization claims from limited samples), reviewers are asked whether the data and analyses fully support the claims, and the editors weigh that in their decision. The strongest manuscripts make conservative conclusions that the data clearly support.

Check whether your conclusions stay inside the data →

We have reviewed 50+ manuscripts targeting PLOS Medicine, BMJ, The Lancet, BMC Medicine, PLOS ONE, and adjacent clinical-research venues. Full Manusights reviews include a 60-day money-back guarantee, and we do not train models on your manuscript.

In our pre-submission review work across general-medicine and clinical-research targets, we see five recurring preventable risks before peer review: specialty-only framing, unsupported policy or practice claims, under-specified statistical methods, incomplete data-availability routes, and reporting checklists that do not map cleanly to the manuscript. Source limitation: Official guidance explains the process, publication criteria, and portal route, but it cannot diagnose whether your specific abstract, tables, methods, and data package will satisfy the professional editor and Academic Editor.

This page was created from PLOS Medicine's public Editorial and Peer Review Process documentation at Journals editorial team page, PLOS Medicine submission guidelines documentation (initial assessment by a staff editor and Academic Editor, criteria-based publication decisions, optional published peer review history), SciRev community-reported transit data on PLOS Medicine, and Manusights pre-submission review experience with PLOS Medicine-targeted manuscripts.

For the PLOS general-medicine landscape beyond PLOS Medicine, see PLOS ONE (technically-sound open-access cascade), PLOS Global Public Health (global-health specialty), PLOS Digital Health (digital-health and AI-clinical-research specialty), and external general-medicine open-access alternatives (BMJ Open, The Lancet Public Health, NEJM Evidence).

The choice across these titles depends on whether the central contribution is top-tier PLOS general-medicine clinical-research (PLOS Medicine), technically-sound open-access (PLOS ONE), global-health-focused (PLOS Global Public Health), digital-health-focused (PLOS Digital Health), or external general-medicine open-access (BMJ Open, Lancet Public Health, NEJM Evidence).

PLOS Medicine says that, where relevant, the statistical methods in a manuscript undergo rigorous review. Editors screen and triage manuscripts before external reviewers see them, and preparing a response template that addresses both general-medicine relevance and methods detail accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the PLOS Medicine general-medicine-relevance-plus-methods-detail bar before submission, our PLOS Medicine pre-submission diagnostic flags the framing and methods-documentation weaknesses most likely to surface in reviewer reports.